WASHINGTON (March 27, 2025) — The Association for Accessible Medicines today congratulated Dr. Marty Makary, MD, MPH on his confirmation as Commissioner of the Food and Drug Administration.
“AAM and the Biosimilars Council congratulate Dr. Makary on his confirmation by the Senate as FDA Commissioner,” said John Murphy III, President and CEO of AAM. “Ensuring that all Americans have access to safe, effective, and affordable medicines is essential to public health. Generic and biosimilar medicines are the foundation of pharmaceutical cost savings, delivering high-quality treatments while reducing health care expenses. We look forward to collaborating with Dr. Makary and the dedicated team at the FDA to enhance efficiency, modernize regulatory pathways, and strengthen a sustainable, competitive pharmaceutical market that benefits patients nationwide.”
AAM also recognizes the critical role of the FDA’s highly skilled staff in ensuring timely reviews of generic and biosimilar medicines. A fully resourced FDA is essential to maintaining an efficient and science-based regulatory process that supports innovation, ensures drug availability, and prevents delays that could impact patient access to affordable treatments. We stand ready to work with Dr. Makary and Congress to ensure that the FDA has the resources and staffing needed to fulfill its mission and keep life-saving medicines accessible to all Americans.
For media inquiries, contact media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.
